JPRN-UMIN000027211已完成2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies, accompanying research(WJOG8916GTR) - A phase II trial of TAS-102 in combination with cetuximab for metastatic colorectal cancer patients, accompanying research(WJOG8916GTR)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G)Metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti-epidermal growth factor receptor(EGFR) antibodiesJPRN-UMIN000027210West Japan Oncology Group55
已完成
1 期
A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapiesadvanced gastric cancer refractory to standard chemotherapiesJPRN-UMIN000031346St. Marianna University School of Medicine11
已完成
2 期
Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapyadvanced gastric cancerJPRN-UMIN000007421ational Cancer Center Hospital East28
已完成
1 期
Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.advanced colorectal cancerJPRN-UMIN000012883ational Cancer Center Exploratory Oncology Research &Clinical Trial Center25
已完成
2 期
A phase II study of TAS102 for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxanenresectable, advanced or recurrent esophageal cancerJPRN-UMIN000019268Kyoto University Hospital40